NTLA vs. SE

Last updated Apr 2, 2026

Compare and contrast key facts about Intellia Therapeutics, Inc. (NTLA) and Sea Limited (SE).

Performance

NTLA vs. SE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Intellia Therapeutics, Inc. (NTLA) and Sea Limited (SE). The values are adjusted to include any dividend payments, if applicable.

NTLA vs. SE - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
NTLA Intellia Therapeutics, Inc.	47.61%	-22.90%	-61.76%	-12.61%	-70.49%	117.35%	270.82%	7.47%	-28.98%	-31.89%
SE Sea Limited	-35.60%	20.24%	161.98%	-22.16%	-76.74%	12.39%	394.90%	255.30%	-15.08%	-18.02%

Fundamentals

Market Cap NTLA : $1.44B SE : $52.54B
EPS NTLA : -$3.84 SE : $2.55
PB Ratio NTLA : 2.14 SE : 4.19
Total Revenue (TTM) NTLA : $0.00 SE : $22.94B
Gross Profit (TTM) NTLA : -$34.30M SE : $10.24B
EBITDA (TTM) NTLA : -$322.22M SE : $2.21B

Returns By Period

In the year-to-date period, NTLA achieves a 47.61% return, which is significantly higher than SE's -35.60% return.

NTLA

• 1D: 3.51%
• 1M: -14.05%
• YTD: 47.61%
• 6M: -29.26%
• 1Y: 99.40%
• 3Y*: -29.12%
• 5Y*: -30.19%
• 10Y*: —

SE

• 1D: -0.78%
• 1M: -21.91%
• YTD: -35.60%
• 6M: -54.86%
• 1Y: -37.97%
• 3Y*: -1.72%
• 5Y*: -19.06%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

NTLA vs. SE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NTLA

NTLA Risk / Return Rank: 70
NTLA Sharpe Ratio Rank: 73
NTLA Sortino Ratio Rank: 72
NTLA Omega Ratio Rank: 75
NTLA Calmar Ratio Rank: 66
NTLA Martin Ratio Rank: 61

SE

SE Risk / Return Rank: 13
SE Sharpe Ratio Rank: 10
SE Sortino Ratio Rank: 12
SE Omega Ratio Rank: 12
SE Calmar Ratio Rank: 20
SE Martin Ratio Rank: 13

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NTLA vs. SE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Intellia Therapeutics, Inc. (NTLA) and Sea Limited (SE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	NTLA	SE	Difference
Sharpe ratio Return per unit of total volatility	0.99	-0.73	+1.72
Sortino ratio Return per unit of downside risk	1.74	-0.89	+2.63
Omega ratio Gain probability vs. loss probability	1.25	0.88	+0.37
Calmar ratio Return relative to maximum drawdown	1.22	-0.62	+1.83
Martin ratio Return relative to average drawdown	2.17	-1.36	+3.52
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

NTLA vs. SE - Sharpe Ratio Comparison

The current NTLA Sharpe Ratio is 0.99, which is higher than the SE Sharpe Ratio of -0.73. The chart below compares the historical Sharpe Ratios of NTLA and SE, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	NTLA	SE	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.99	-0.73	+1.72
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.38	-0.30	-0.08
Sharpe Ratio (All Time) Calculated using the full available price history	-0.06	0.34	-0.40

Correlation

The correlation between NTLA and SE is 0.35, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

NTLA vs. SE - Dividend Comparison

Neither NTLA nor SE has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

NTLA vs. SE - Drawdown Comparison

The maximum NTLA drawdown since its inception was -96.45%, which is greater than SE's maximum drawdown of -90.51%. Use the drawdown chart below to compare losses from any high point for NTLA and SE.

Drawdown Indicators

	NTLA	SE	Difference
Max Drawdown Largest peak-to-trough decline	-96.45%	-90.51%	-5.94%
Max Drawdown (1Y) Largest decline over 1 year	-71.27%	-60.22%	-11.05%
Max Drawdown (5Y) Largest decline over 5 years	-96.45%	-90.51%	-5.94%
Current Drawdown Current decline from peak	-92.49%	-77.61%	-14.88%
Average Drawdown Average peak-to-trough decline	-56.43%	-43.36%	-13.07%
Ulcer Index Depth and duration of drawdowns from previous peaks	39.98%	27.31%	+12.67%

Volatility

NTLA vs. SE - Volatility Comparison

Intellia Therapeutics, Inc. (NTLA) has a higher volatility of 17.93% compared to Sea Limited (SE) at 14.95%. This indicates that NTLA's price experiences larger fluctuations and is considered to be riskier than SE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	NTLA	SE	Difference
Volatility (1M) Calculated over the trailing 1-month period	17.93%	14.95%	+2.98%
Volatility (6M) Calculated over the trailing 6-month period	85.04%	36.91%	+48.13%
Volatility (1Y) Calculated over the trailing 1-year period	101.32%	52.29%	+49.03%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	80.73%	64.17%	+16.56%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	78.27%	62.82%	+15.45%

Financials